HHV-8/KSHV is a persistent gammaherpesvirus capable of establishing lifelong infection. In a subset of individuals, particularly when immune surveillance is weakened, the virus is linked to several malignancies, including primary effusion lymphoma and multicentric Castleman disease-associated lymphoproliferative disorders. These diseases arise from abnormal B cells carrying viral genetic material and are often biologically aggressive. KSHV does not simply transform cells through a single molecular switch. Instead, it uses a coordinated program of viral proteins and noncoding RNAs to alter cellular signaling, proliferation, apoptosis, inflammatory responses and immune recognition. The virus also manipulates the epigenetic landscape of its host cell, creating conditions that support latency, survival and malignant development. This makes chromatin-modifying enzymes attractive targets for therapies designed to expose vulnerabilities shared by the virus and the tumor.

KDM5A and KDM5B belong to the Jumonji C-domain family of histone demethylases. Their principal biochemical function is the removal of methyl groups from lysine 4 on histone H3, particularly the transcription-associated marks H3K4me2 and H3K4me3. Because these histone modifications are frequently found near active promoters and enhancers, KDM5 enzymes can influence whether immune, stress-response and growth-control genes are available for transcription. Their activity is not equivalent to a simple on-or-off switch: the effect depends on genomic location, interacting proteins and the wider chromatin environment. In cancer, elevated or misdirected KDM5 activity has been associated with transcriptional plasticity, treatment resistance and the maintenance of stem-like cell states. In virus-associated malignancies, these enzymes may also help maintain a cellular state that tolerates persistent infection while limiting the expression of genes capable of alerting the immune system.

The central implication of the study is that inhibiting KDM5A and KDM5B can release an antitumor innate immune program in HHV-8/KSHV-positive B-cell lymphomas. Innate immunity provides the rapid, first-line system for detecting infection and cellular danger. It relies on sensors that recognize viral nucleic acids, abnormal patterns of gene expression or signs of cellular stress. Once activated, these pathways can stimulate transcription factors such as interferon regulatory factors and NF-κB, leading to production of type I interferons, inflammatory cytokines and chemokines. These signals can restrict viral replication, recruit immune cells and increase the visibility of malignant cells. The research therefore points to KDM5A/B inhibition as a way of altering the transcriptional state of lymphoma cells so that they become more immunologically conspicuous, rather than remaining protected within a virus-shaped state of immune evasion.

This concept is especially significant in KSHV-associated disease because viral latency depends on a delicate balance. The virus must preserve the infected cell and maintain its own genetic program without generating an immune alarm strong enough to eliminate the host cell. KSHV-associated tumors often express only a limited subset of viral genes, while cellular pathways are extensively remodeled to support survival and proliferation. Epigenetic repression can help enforce this restricted expression pattern and suppress host defense genes at the same time. If KDM5A and KDM5B inhibition reverses part of that repression, the result may be a broader change in the tumor microenvironment: infected malignant cells could produce more immune-stimulating signals, while neighboring immune cells receive stronger cues to respond. The therapeutic value would not necessarily depend on forcing the virus into a fully active replicative phase, but on making the tumor less capable of hiding from immune surveillance.

The findings also illustrate why innate immune activation is becoming an important objective in cancer drug development. Many immunotherapies depend on pre-existing immune recognition, yet virus-associated lymphomas may suppress the signals required to initiate that recognition. Epigenetic inhibitors could help solve this problem by functioning as immune-priming agents. In principle, a KDM5A/B inhibitor might increase the expression of interferon-stimulated genes, antigen-processing components or chemokines that promote the recruitment of natural killer cells and other immune effectors. Such changes could complement treatments that act directly on immune checkpoints or on the malignant B-cell compartment. However, the biological effects of chromatin drugs are context-dependent. The same intervention can activate beneficial defense pathways in one tumor while producing toxicity, unwanted inflammation or compensatory survival responses in another. The study consequently supports a strategy that combines molecular targeting with careful analysis of the immune state of each lymphoma.

The work is also relevant to a broader question in viral oncology: whether the epigenetic dependencies of a cancer can be therapeutically separated from the normal functions of the infected tissue. KDM5A and KDM5B regulate gene expression in healthy cells as well as tumor cells, so selective treatment will require attention to dose, exposure and the molecular features of individual tumors. HHV-8/KSHV-positive lymphomas are not uniform. They can differ in viral gene expression, cellular mutations, inflammatory signaling and sensitivity to immune attack. Determining which tumors depend most strongly on KDM5A/B activity, and which transcriptional changes predict a response, will be essential for translating the findings into clinical trials. Biomarkers might include KDM5A/B abundance, histone methylation patterns, interferon-response signatures or measures of viral latency, although their usefulness would need to be established experimentally.

The study further raises the possibility that chromatin-directed therapy could influence both sides of the infection-cancer relationship. Inhibiting KDM5A/B may weaken tumor-cell fitness through changes in growth and survival genes while simultaneously improving immune detection. These effects could reinforce one another: a stressed lymphoma cell may be more vulnerable to immune-mediated killing, and a stronger innate response may prevent surviving cells from re-establishing a protected malignant state. Yet viral tumors are adept at adapting. KSHV encodes multiple mechanisms that interfere with innate sensing, interferon signaling and antigen presentation, and these defenses may remain active even after epigenetic repression is relieved. Future work will therefore need to determine how KDM5A/B inhibition interacts with viral immune-evasion proteins, whether it changes the balance between latent and lytic infection, and how immune cells in the surrounding tissue respond to treated lymphoma cells.

For patients with HHV-8/KSHV-positive B-cell lymphomas, the report offers a mechanistically informed avenue for therapeutic development rather than an immediate clinical treatment. Its importance lies in connecting a defined class of epigenetic enzymes with the immune behavior of a virus-driven cancer. By identifying KDM5A/B inhibition as a means of promoting antitumor innate immunity, Zhou, Fiches, Wu and colleagues extend the search for KSHV therapies beyond conventional cytotoxic drugs and direct antiviral approaches. The next stages will require validation in disease-relevant models, assessment of drug selectivity and toxicity, and testing of rational combinations with immune-based or lymphoma-directed treatments. If those studies confirm that epigenetic release of innate immune programs can be achieved safely, KDM5A and KDM5B could become part of a new therapeutic framework in which the tumor’s hidden viral biology is converted into an exploitable immune vulnerability.

Subject of Research: KDM5A/B inhibition, antitumor innate immunity, and HHV-8/KSHV-positive B-cell lymphomas

Article Title: Inhibition of KDM5A/B promotes antitumor innate immune responses in HHV-8/KSHV-positive B-cell lymphomas

Article References: Zhou, D., Fiches, G.N., Wu, Z. et al. “Inhibition of KDM5A/B promotes antitumor innate immune responses in HHV-8/KSHV-positive B-cell lymphomas.” npj Viruses (2026). https://doi.org/10.1038/s44298-026-00223-3

Image Credits: AI Generated

DOI: 10.1038/s44298-026-00223-3

Keywords: HHV-8, KSHV, B-cell lymphoma, KDM5A, KDM5B, epigenetics, innate immunity, viral oncology, immunotherapy

Central to herpesvirus infectivity is the glycoprotein B (gB), an evolutionarily conserved fusion protein that mediates viral entry into host cells. This protein is indispensable across herpesvirus subfamilies, orchestrating membrane fusion events vital for viral replication and spread. The universality of gB among herpesviruses has positioned it as an attractive candidate for the development of broad-spectrum vaccines and therapeutics. However, the feasibility of targeting gB across diverse gammaherpesvirus genera has remained elusive, largely due to the absence of molecular insights that characterize its antigenic profile and functional vulnerabilities on a structural basis.

The research team has now bridged this gap by characterizing a monoclonal antibody named Fab5, which exhibits remarkable cross-genus reactivity by binding a conserved epitope on gammaherpesvirus gB. Fab5’s broad neutralization capacity transcends species boundaries, effectively inhibiting murine gammaherpesvirus 68 (MHV-68), rhesus macaque lymphocryptovirus, and human gammaherpesviruses. This cross-protective efficacy was demonstrated through rigorous in vivo challenges utilizing immune-competent mouse models, non-human primates, and humanized mice, establishing Fab5’s promise as a versatile immunotherapeutic agent for gammaherpesvirus infection.

Employing high-resolution cryogenic electron microscopy (cryo-EM), the investigators elucidated the three-dimensional architecture of the Fab5-gB complex. Structural data revealed that Fab5 targets an epitope exhibited on a highly conserved domain of gB, accessible in both pre-fusion and post-fusion conformations. This epitope is antigenically exposed and structurally constrained, underscoring its vulnerability to antibody engagement. Such dual conformation accessibility amplifies the neutralization breadth of Fab5, suggesting a mechanism whereby the antibody can intercept viral fusion machinery at multiple stages of the entry process.

This discovery carries profound implications for understanding gammaherpesvirus pathogenesis. The conserved nature of the gB epitope signifies an evolutionary pressure maintaining this region’s integrity despite viral diversification, pointing to its essential role in membrane fusion and infectivity. Fab5’s engagement likely disrupts critical conformational rearrangements required for fusion pore formation, thus halting the virus life cycle early and preventing cell-to-cell spread.

Moreover, these insights catalyze the rational design of next-generation broad-spectrum vaccines. By focusing immunogen development on this universal gB epitope, vaccine candidates may elicit robust cross-protective immunity against multiple gammaherpesviruses. This approach contrasts starkly with current vaccine strategies that predominantly target highly variable viral antigens, often resulting in strain-specific responses with limited durability and range.

The translational potential is underscored by the antibody’s efficacy in non-human primate models, which closely recapitulate human immune responses and gammaherpesvirus pathogenesis. Such preclinical validation enhances confidence in advancing Fab5-based therapeutics into clinical evaluation. Furthermore, the antibody’s ability to neutralize both latent and lytic phases of the viral lifecycle could revolutionize treatment paradigms for associated cancers and chronic infections, which often evade conventional antiviral strategies.

This study also opens avenues for exploring analogous fusion proteins in other herpesvirus subfamilies. Given that gB is conserved yet structurally distinct across alphaherpesviruses and betaherpesviruses, the methodological framework established here may guide the search for broadly neutralizing antibodies against these groups. A unified understanding of herpesvirus fusion mechanisms may thus emerge, unlocking pan-herpesvirus vaccination and treatment strategies.

Additionally, the Fab5-gB structural complex provides a template for designing small molecule inhibitors or engineered antibody derivatives with enhanced stability, affinity, and pharmacokinetics. Such modalities could complement active vaccination efforts, offering immediate protection for immunocompromised individuals or in outbreak containment scenarios. The integration of structural biology, immunology, and in vivo validation embodied in this research sets a benchmark for antiviral drug discovery.

In sum, the identification of Fab5 as a broadly reactive antibody against a conserved, vulnerable epitope of gammaherpesvirus gB represents a milestone in herpesvirus biology and therapeutic innovation. It signifies a new horizon wherein structural-guided immunotherapy enables cross-species viral neutralization, mitigating the global health burden posed by gammaherpesvirus infections and associated malignancies. The profound translational promise of this work invites intensified efforts toward clinical development, with the prospect of delivering transformative interventions for patients worldwide.

Subject of Research:
Broad neutralization of gammaherpesviruses via a conserved glycoprotein B (gB)-targeting antibody.

Article Title:
A broadly protective antibody targeting gammaherpesvirus gB.

Article References:
Sun, C., Xie, C., Cheng, BZ. et al. A broadly protective antibody targeting gammaherpesvirus gB. Nature (2026). https://doi.org/10.1038/s41586-026-10192-5

Image Credits:
AI Generated

Kaposi’s sarcoma-associated herpesvirus, also known as human herpesvirus 8, is well recognized for its association with malignancies, including Kaposi’s sarcoma and certain lymphomas, primarily in immunocompromised patients. While its oncogenic facets have been intensively studied, the intricate mechanisms by which KSHV modulates cellular environments to facilitate its lifecycle remain incompletely understood. This new study focuses on an often-overlooked aspect of viral strategy: the manipulation of mitochondrial dynamics to circumvent immune surveillance and favor productive infection.

Central to this viral manipulation is a protein encoded by KSHV homologous to the cellular Bcl-2 family, denoted as viral Bcl-2 (vBcl-2). Unlike its cellular counterparts, which primarily regulate apoptosis, this viral incarnation assumes a more multifaceted role. Zhu et al. demonstrate that vBcl-2 effectively reprograms mitochondrial morphology, favoring fission over fusion—a state characterized by fragmented, punctate mitochondria. The researchers elucidate a direct molecular interaction underpinning this morphological shift, spotlighting the host nucleoside diphosphate kinase NM23-H2 as a critical partner in this process.

NM23-H2 is classically known for its enzymatic activity in nucleotide metabolism, catalyzing the transfer of γ-phosphates among nucleoside diphosphates and triphosphates. In this context, however, it assumes a novel role as a facilitator of mitochondrial fission through its partnership with vBcl-2. The viral protein binds NM23-H2, which subsequently stimulates GTP loading on dynamin-related protein 1 (DRP1), a GTPase crucial for mitochondrial fission. This biochemical activation prompts DRP1 to oligomerize on the mitochondrial outer membrane, driving the mechanical processes that fragment the organelle.

This mitochondrial fragmentation is no incidental side effect. Rather, it strategically dampens host antiviral signaling by disrupting the function of mitochondria-anchored antiviral proteins. One key player is the mitochondrial antiviral signaling protein MAVS, which typically forms aggregates on the outer membrane upon detection of viral RNA. These aggregates serve as platforms to activate downstream signaling cascades culminating in interferon production, a cornerstone of the host’s innate immunity. By inducing mitochondrial fission, KSHV effectively inhibits MAVS aggregation, thereby silencing the interferon response and undermining a crucial antiviral defense.

The authors contrasted the wild-type vBcl-2 with a mutant variant defective in binding NM23-H2, discovering striking differences in functional outcomes. Cells expressing the mutant failed to undergo mitochondrial fission, which correlated with a resurgence of MAVS aggregation and vigorous interferon signaling. This immune activation, in turn, rendered virion assembly defective, underscoring the importance of vBcl-2-mediated mitochondrial reconfiguration in viral progeny production. Thus, the virus’s capacity to trigger mitochondrial fission is directly linked to both immune evasion and successful virion morphogenesis.

Delving deeper into the host response, Zhu et al. identified two interferon-stimulated genes that act as antiviral effectors restricting vBcl-2-dependent virion assembly. While the study does not elaborate extensively on these genes’ identities, their emergence highlights the layered nature of host restriction mechanisms that continue to exert pressure on viral replication even when key pathways like MAVS signaling are subdued. This finding also suggests that therapeutic strategies could aim to bolster or mimic these intrinsic antiviral factors.

The translational potential of these insights was explored through a high-throughput small molecule screening aimed at identifying inhibitors that disrupt the interaction between vBcl-2 and NM23-H2. Among the candidates, the authors discovered a compound capable of selectively obstructing this viral-host protein interface, leading to marked suppression of virion production in vitro. This pharmacological blockade reactivates mitochondrial antiviral signaling by preserving MAVS aggregation, reinstating interferon responses, and curbing virus proliferation.

This study provides a vivid example of how viruses exploit mitochondrial dynamics not only to create a favorable niche for replication but also to actively subvert host immunity. The identification of the vBcl-2 and NM23-H2 interaction as a pivotal node in this manipulation opens new avenues for antiviral drug development which, by targeting host-virus protein interactions, may offer durable therapeutic benefits with reduced likelihood of resistance.

Moreover, these findings compel a broader reevaluation of mitochondrial fission’s role in viral pathogenesis. Traditionally viewed as cellular responses to stress or damage, mitochondrial morphological changes are increasingly recognized as deliberate viral strategies to silence immune barriers. The KSHV case study advances our understanding by revealing a mechanism through which a viral Bcl-2 analog usurps host enzymatic machinery to modulate mitochondrial shape, thus intersecting with innate immunity at a fundamental level.

The implications extend beyond KSHV itself, as many viruses encode Bcl-2 homologs or manipulate mitochondrial dynamics to varying degrees. Understanding how these strategies converge on common host pathways such as DRP1 activation and MAVS suppression offers a framework for investigating immune evasion among diverse viral families. Therapeutic strategies emerging from this paradigm have the potential for broad-spectrum application against pathogens that exploit analogous mitochondrial interfaces.

From a cell biology perspective, this work also enriches the discourse on mitochondrial dynamics by linking it directly to antiviral signaling fidelity. It underscores that mitochondrial morphology is not a simple passive indicator of cellular health but an active modulator of immune signal transduction. This functional duality presents a conceptual leap—considering organelle ultrastructure as a dynamic immunoregulatory element shaped by viral manipulation.

While the study predominantly used in vitro models, the findings invite future in vivo investigations to assess how modulating mitochondrial dynamics affects KSHV pathogenesis and immune responses within an organismal context. Understanding the temporal kinetics of viral-induced mitochondrial fragmentation, its reversibility, and interactions with other host pathways will be critical to translating these molecular insights into tangible clinical interventions.

Collectively, Zhu et al. unveil an elegant viral strategy whereby KSHV encodes a Bcl-2 homolog that commandeers a host nucleotide kinase to activate DRP1-driven mitochondrial fission. This reconfiguration impedes MAVS aggregation, silences interferon responses, and facilitates virion assembly, securing viral propagation. The therapeutic disruption of the vBcl-2–NM23-H2 interaction thereby emerges as a promising avenue to reinstate host immunity and inhibit viral production. This study not only deepens our understanding of mitochondrial dynamics in immunological defense but also highlights a novel antiviral target at the virus-mitochondria interface.

The multidimensional nature of these findings accentuates the sophistication with which viruses exploit host cell biology and reveals mitochondria as a nexus of pathogenic control. It challenges researchers and clinicians alike to consider the organelle as a frontline in the immunological war against infection, ripe for targeted therapeutic intervention.

Subject of Research: Viral manipulation of mitochondrial dynamics to evade host immunity and promote Kaposi’s sarcoma-associated herpesvirus (KSHV) production.

Article Title: Kaposi’s sarcoma-associated herpesvirus induces mitochondrial fission to evade host immune responses and promote viral production.

Article References:
Zhu, Q., McElroy, R., Machhar, J.S. et al. Kaposi’s sarcoma-associated herpesvirus induces mitochondrial fission to evade host immune responses and promote viral production. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02018-3

Image Credits: AI Generated